Published in Aging Cell, the findings show that animals treated with rilmenidine, currently used to treat hypertension, at young and older ages increases lifespan and improves health markers, mimicking the effects of caloric restriction.

发表在《衰老细胞》上的研究结果显示，用目前用于治疗高血压的利美尼丁治疗年轻和年长的动物，可以延长寿命并改善健康指标，相当于模仿热量限制的效果。

They also demonstrate that the healthspan and lifespan benefits of rilmenidine treatment in the roundworm C. elegans are mediated by the I1-imidazoline receptor nish-1, identifying this receptor as a potential longevity target.

他们还证明，利美尼定治疗秀丽隐杆线虫的健康跨度和寿命益处是由i1 -咪唑啉受体nish-1介导的，确定该受体是潜在的长寿目标。

Unlike other drugs previously studied for this purpose by the researchers, the widely-prescribed, oral antihypertensive rilmenidine has potential for future translatability to humans as side-effects are rare and non-severe.

与研究人员以前为此目的研究的其他药物不同，被广泛处方的口服降压药利美尼丁具有未来延长人类寿命的潜力，因为其副作用很少且不严重。

To date, a caloric restriction diet has been considered the most robust anti-aging intervention, promoting longevity across species. However, studies of caloric restriction in humans have had mixed results and side effects, meaning finding medications like rilmenidine that can mimic the benefits of caloric restriction is the most reasonable anti-aging strategy.

迄今为止，限制热量的饮食被认为是最有力的抗衰老干预措施，可促进各物种的长寿。 然而，对人类热量限制的研究结果和副作用参差不齐，这意味着找到像利美尼丁这样可以模仿热量限制益处的药物，是最合理的抗衰老策略。

Professor João Pedro Magalhães, who led the research whilst at the University of Liverpool and is now based at the University of Birmingham, said: "With a global ageing population, the benefits of delaying ageing, even if slightly, are immense. Repurposing drugs capable of extending lifespan and healthspan has a huge untapped potential in translational geroscience. For the first time, we have been able to show in animals that rilmenidine can increase lifespan. We are now keen to explore if rilmenidine may have other clinical applications."

João Pedro Magalhães教授在利物浦大学时领导了这项研究，他现在在伯明翰大学工作，他说。"随着全球人口的老龄化，延迟衰老的好处是巨大的，即使是轻微的延迟。 重新利用能够延长寿命和健康跨度的药物，在转化老年科学方面有着巨大的未开发的潜力。 我们第一次在动物身上证明利美尼丁能够延长寿命。 我们现在热衷于探索利美尼丁是否可能有其他临床应用"。

This study was undertaken by researchers from the University of Liverpool, ETH Zürich and Harvard Medical School, and funded by the Swiss National Science Foundation, LongeCity and the Biotechnology and Biological Sciences Research Council.

这项研究由利物浦大学、苏黎世联邦理工学院和哈佛大学医学院的研究人员进行，并由瑞士国家科学基金会、LongeCity和生物技术与生物科学研究委员会资助。